Terbinafine
Product Images NDC 68788-7722

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 68788-7722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terbinaine Tablet 250mg (250mg 30tabs)

This is a description for the medication Terbinafine Tablet, prescribed as a generic for Lamisil Progt. Each tablet contains Terbinafine HCl eq. f bt e el B et s in the strength of 250mg. The tablets should be protected from light and stored at a temperature between 65 to 77°F. The medication should not be transferred or taken by anyone other than the patient it was prescribed for. The given batch and expiration date is not readable from the text.*

FDA Label Image

Image 2 (Terbinafine Str)

FDA Label Image

Image 1 (Terbinafine Table)

This is a table of adverse events and discontinuation percentages of Terbinafine Tablets and Placebo Tablets. The adverse events are categorized under gastrointestinal, dermatological, liver enzyme abnormalities, taste and visual disturbances which are represented by percentages for different symptoms. The table is showing that Terbinafine Tablets are associated with higher incidence of adverse events.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.